Gene · 1830
Papers2,614
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,614
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Anti-Desmoglein 3 Avidity Correlates Better With Pemphigus Vulgaris Severity Than Anti-Desmoglein 3 Concentration. | Int J Dermatol | 2026 | 41670289 | PubTator, text mining | PubMed |
| Pemphigus Foliaceus Mimicking Erythema Annulare Centrifugum: A Case Report. | Cureus | 2026 | 41646576 | PubTator, text mining | PubMed |
| CAR-T cell therapy: A new dawn in the treatment of autoimmune disease. | Cell Transplant | 2026 | 41558532 | PubTator, text mining | PubMed |
| Clinical Phenotype Transition in Pemphigus May Suggest Undertreatment with Rituximab: Findings from a Retrospective Single-Centre Analysis of Relapsed Patients. | Dermatology | 2026 | 41553945 | PubTator, text mining | PubMed |
| Persistence of anti-desmoglein 3 antibodies in patients with pemphigus vulgaris in complete remission is associated with restricted isotype diversity and desmoglein 3 ectodomain recognition. | Br J Dermatol | 2026 | 41508790 | PubTator, text mining | PubMed |
| Inhibition of the JAK/STAT Signaling Pathway Suggests a Protective Effect against Acantholysis in Pemphigus. | Inflammation | 2026 | 41491145 | PubTator, text mining | PubMed |
| Emerging Treatments in Pemphigus: Is Healing an Achievable Goal? | Am J Clin Dermatol | 2026 | 41460304 | PubTator, text mining | PubMed |
| Clinical and Immunological Outcomes of Rituximab Therapy in Pemphigus: A Prospective Observational Study. | Dermatology | 2026 | 41442437 | PubTator, text mining | PubMed |
| Urothelium marker UPK2 identifies aggressive colorectal cancers with distinct molecular and histological features. | Br J Cancer | 2026 | 41381844 | PubTator, text mining | PubMed |
| Role of protein kinase C subtype-specific signalling in regulating adhesion in human keratinocytes and skin in pemphigus. | Br J Dermatol | 2026 | 41239864 | PubTator, text mining | PubMed |
| Patterns of circulating autoantibodies against desmoglein-1 and desmoglein-3 in the progression of oral lichen planus: A scoping review. | Arch Oral Biol | 2026 | 41129925 | PubTator, text mining | PubMed |
| Deep Analysis of Desmoglein-3-Reactive CD4+ T Cells in Pemphigus Vulgaris Reveals a Type 17/Type 2 T-Cell Signature. | J Invest Dermatol | 2026 | 40930459 | PubTator, text mining | PubMed |
| Widespread Blistering on Day One in a Neonate. | Indian Dermatol Online J | 2026 | 40924706 | PubTator, text mining | PubMed |
| Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus. | Br J Dermatol | 2026 | 40795222 | PubTator, text mining | PubMed |
| Intralesional Rituximab in Recalcitrant Oral and Scalp Lesions of Pemphigus: A Retrospective Study. | Int J Dermatol | 2026 | 40747791 | PubTator, text mining | PubMed |
| The Multikinase Inhibitor Midostaurin Mitigates Loss of Intercellular Adhesion and Skin Blistering in Pemphigus Vulgaris. | J Invest Dermatol | 2026 | 40449656 | PubTator, text mining | PubMed |
| An Update on Pemphigus Vulgaris in Pregnancy and Neonates: Management Options and Our Clinical-Laboratory Experience. | Medicina (Kaunas) | 2025 | 41597317 | PubTator, text mining | PubMed |
| TMEtyper: A computational method for tumor microenvironment subtyping with applications in immunotherapy. | Comput Struct Biotechnol J | 2025 | 41542078 | PubTator, text mining | PubMed |
| Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab. | Front Immunol | 2025 | 41459496 | PubTator, text mining | PubMed |
| Immunoprofile of some transmembrane adhesion molecules in oral squamous cell carcinoma. | Rom J Morphol Embryol | 2025 | 41382943 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1830/papers?page=3